Literature DB >> 32084361

Toll-Like Receptor-4 Antagonist (+)-Naltrexone Protects Against Carbamyl-Platelet Activating Factor (cPAF)-Induced Preterm Labor in Mice.

Hanan H Wahid1, Peck Yin Chin1, David J Sharkey1, Kerrilyn R Diener2, Mark R Hutchinson3, Kenner C Rice4, Lachlan M Moldenhauer1, Sarah A Robertson5.   

Abstract

Spontaneous preterm labor is frequently caused by an inflammatory response in the gestational tissues elicited by either infectious or sterile agents. In sterile preterm labor, the key regulators of inflammation are not identified, but platelet-activating factor (PAF) is implicated as a potential rate-limiting effector agent. Since Toll-like receptor (TLR)-4 can amplify PAF signaling, we evaluated whether TLR4 contributes to inflammation and fetal loss in a mouse model of PAF-induced sterile preterm labor, and whether a small-molecule TLR4 inhibitor, (+)-naltrexone, can mitigate adverse PAF-induced effects. The administration of carbamyl (c)-PAF caused preterm labor and fetal loss in wild-type mice but not in TLR4-deficient mice. Treatment with (+)-naltrexone prevented preterm delivery and alleviated fetal demise in utero elicited after cPAF administered by i.p. or intrauterine routes. Pups born after cPAF and (+)-naltrexone treatment exhibited comparable rates of postnatal survival and growth to carrier-treated controls. (+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes Il1b, Il6, and Il10 in the decidua; Il6, Il12b, and Il10 in the myometrium; and Il1b and Il6 in the placenta. These data demonstrate that the TLR4 antagonist (+)-naltrexone inhibits the inflammatory cascade induced by cPAF, preventing preterm birth and perinatal death. The inhibition of TLR4 signaling warrants further investigation as a candidate strategy for fetal protection and delay of preterm birth elicited by sterile stimuli.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32084361      PMCID: PMC7237831          DOI: 10.1016/j.ajpath.2020.01.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  88 in total

1.  Platelet-activating factor antagonist WEB-2170 inhibits lipopolysaccharide-induced, but not antiprogestin-induced, preterm cervical ripening in timed-pregnant rats.

Authors:  Holger Maul; Leili Shi; Stephen G Marx; Robert E Garfield; George R Saade
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

2.  Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation.

Authors:  Y Cao; D M Stafforini; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

3.  Corticotrophin-releasing hormone and platelet-activating factor induce transcription of the type-2 cyclo-oxygenase gene in human fetal membranes.

Authors:  S A Alvi; N L Brown; P R Bennett; M G Elder; M H Sullivan
Journal:  Mol Hum Reprod       Date:  1999-05       Impact factor: 4.025

4.  Dynamic changes in cervical glycosaminoglycan composition during normal pregnancy and preterm birth.

Authors:  Yucel Akgul; Roxane Holt; Mark Mummert; Ann Word; Mala Mahendroo
Journal:  Endocrinology       Date:  2012-04-23       Impact factor: 4.736

5.  Effects of platelet-activating factor on cytokine production by human uterine cervical fibroblasts.

Authors:  T Sugano; H Narahara; K Nasu; K Arima; K Fujisawa; I Miyakawa
Journal:  Mol Hum Reprod       Date:  2001-05       Impact factor: 4.025

Review 6.  Toll-like Receptor-4: A New Target for Preterm Labour Pharmacotherapies?

Authors:  Sarah A Robertson; Hanan H Wahid; Peck Yin Chin; Mark R Hutchinson; Lachlan M Moldenhauer; Jeffrey A Keelan
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

7.  Toll-Like Receptor-4 Antagonist (+)-Naloxone Confers Sexually Dimorphic Protection From Inflammation-Induced Fetal Programming in Mice.

Authors:  Peck Yin Chin; Camilla Dorian; David J Sharkey; Mark R Hutchinson; Kenner C Rice; Lachlan M Moldenhauer; Sarah A Robertson
Journal:  Endocrinology       Date:  2019-11-01       Impact factor: 4.736

8.  Toll receptor 4 Asp299Gly polymorphism and its association with preterm birth and premature rupture of membranes in a South American population.

Authors:  G Rey; F Skowronek; J Alciaturi; J Alonso; B Bertoni; R Sapiro
Journal:  Mol Hum Reprod       Date:  2008-08-22       Impact factor: 4.025

9.  The role of platelet-activating factor in human fetal lung maturation.

Authors:  D R Hoffman; C T Truong; J M Johnston
Journal:  Am J Obstet Gynecol       Date:  1986-07       Impact factor: 8.661

10.  Surfactant protein secreted by the maturing mouse fetal lung acts as a hormone that signals the initiation of parturition.

Authors:  Jennifer C Condon; Pancharatnam Jeyasuria; Julie M Faust; Carole R Mendelson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-25       Impact factor: 11.205

View more
  6 in total

1.  Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal-fetal inflammation in mice.

Authors:  Jose Galaz; Roberto Romero; Marcia Arenas-Hernandez; Marcelo Farias-Jofre; Kenichiro Motomura; Zhenjie Liu; Naoki Kawahara; Catherine Demery-Poulos; Tzu Ning Liu; Justin Padron; Bogdan Panaitescu; Nardhy Gomez-Lopez
Journal:  BMC Pregnancy Childbirth       Date:  2022-06-20       Impact factor: 3.105

Review 2.  Next generation strategies for preventing preterm birth.

Authors:  Hannah C Zierden; Rachel L Shapiro; Kevin DeLong; Davell M Carter; Laura M Ensign
Journal:  Adv Drug Deliv Rev       Date:  2021-04-23       Impact factor: 17.873

Review 3.  Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.

Authors:  Sarah A Robertson; Mark R Hutchinson; Kenner C Rice; Peck-Yin Chin; Lachlan M Moldenhauer; Michael J Stark; David M Olson; Jeffrey A Keelan
Journal:  Clin Transl Immunology       Date:  2020-04-14

4.  Macrophages exert homeostatic actions in pregnancy to protect against preterm birth and fetal inflammatory injury.

Authors:  Nardhy Gomez-Lopez; Valeria Garcia-Flores; Peck Yin Chin; Holly M Groome; Melanie T Bijland; Kerrilyn R Diener; Roberto Romero; Sarah A Robertson
Journal:  JCI Insight       Date:  2021-10-08

5.  Preterm Delivery: Microbial Dysbiosis, Gut Inflammation and Hyperpermeability.

Authors:  Silvia Arboleya; David Rios-Covian; Flore Maillard; Philippe Langella; Miguel Gueimonde; Rebeca Martín
Journal:  Front Microbiol       Date:  2022-02-04       Impact factor: 5.640

6.  Preterm Birth Therapies to Target Inflammation.

Authors:  Ioannis Pavlidis; Sarah J Stock
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.